Streetwise Reports' Article Archives — February 2017 back to current month (39)
Aside from the exuberance surrounding the tops of bull markets, the general investment public is uninterested and underinvested in natural resource equities, says Matt Geiger, founder of MJG Capital Limited Partners. Geiger views the general apathy toward natural resources as an opportunity, and profiles three companies that he believes are in position to break away from the herd.
Millennium Minerals, an Accident Waiting to Happen (02/28/2017)
Bob Moriarty of 321 Gold dissects Millennium Minerals' latest moves in Australia.
Canada Zinc: Right Time, Right Metal (02/27/2017)
321 Gold founder Bob Moriarty turns his attention to Canada Zinc, a company that has a giant zinc deposit in northern British Columbia.
With OPEC producers complying with a deal to reduce output to address the oil glut that drove prices down in 2016, the oil price has rebounded above $55 per barrel, and investors are optimistic about a bullish energy market.
Pretium Resources is ramping up Brucejack ahead of schedule and the $100 million offering the company just closed will fund working capital requirements for its start-up.
Major Funds Betting On Trump Sector (02/25/2017)
Donald Trump's presidency is a real nitro boost for the future of the biotech sector in the U.S., says Tom Beck, editor of Portfolio Wealth Global.
Jack Chan's Weekly Gold and Silver Update (02/25/2017)
Technical analyst Jack Chan charts the latest moves in the gold and silver sectors.
The Critical Investor takes an in-depth look at Genesis Metals, which is developing a new geologic model for its 100%-owned flagship Chevrier Gold deposit in Quebec.
GFG Resources has closed a CA$5 million bought-deal financing, securing funding for ongoing exploration at its flagship Rattlesnake Hills gold project in Wyoming.
Uranium has risen 30% from the very low prices of late last year and a trio of analysts agrees that Energy Fuels is in position to take advantage of a rising price environment.
Balmoral's string of assay results released over the last few weeks includes new discoveries as well as extensions of high-grade zones on its Quebec properties.
Seabridge Gold's recent announcement of an increased resource estimate at its KSM project caught the attention of one analyst, and follows another announcement that the company intends to purchase a project that potentially intersects three of Nevada's well-known gold trends.
Buckle Up: Inflation at 58-Month High (02/23/2017)
The stage has been set for high levels of uncertainly, and with uncertainty comes opportunities in commodities, posits Lior Gantz, editor of Wealth Research Group, who also sees opportunities in disruptive technologies in the medical arena.
As Viveve Medical ramped up its U.S. sales force, reported record earnings, increased the number of countries that have given regulatory approval and saw the results of its VIVEVE I clinical study published in the Journal of Sexual Medicine, a trio of analysts took notice.
The Critical Investor profiles Atlantic Gold, which expects to commission its Moose River gold mine in Nova Scotia by the end of this year.
Jack Chan: Buy Zones in an Oil Bull Market (02/18/2017)
Technical analyst Jack Chan charts the latest moves in energy market, noting a major buy signal.
Jack Chan's Weekly Gold and Silver Update (02/18/2017)
Technical analyst Jack Chan charts the latest moves in the precious metals sector.
Stocks in all areas of life sciences including biotech to pharma have been on a roller coaster since Donald Trump won the election in November. Wealth advisor Kristin McFarland discusses the big picture for pharmaceutical investment under the new administration.
TerraX has been moving full speed ahead exploring its large land package at the Yellowknife City Gold project, an area with historic high-grade mines, that experts predict could become a district-scale project.
BT Global Growth's game plan is to go long and short on a wide range of investments, but in this interview with The Gold Report, Paul Beattie, cofounder and managing director of the hedge fund, focuses on four undervalued extraction companies on which the fund is definitely long.
Remembering the Genius of Hunter S. Thompson (02/13/2017)
Precious metals expert Michael Ballanger ponders the timelessness of Hunter S. Thompson's "blistering attacks on the status quo" and their applicability to today's political landscape. He also reminds us of the "incredibly bullish" fundamentals for silver and lays out the evidence for why this precious metal is on its way to $25/ounce by mid-year.
Jack Chan Finds Data Supportive of Higher Oil Prices (02/11/2017)
Technical Analyst Jack Chan reads the charts and sees a major buy signal for energy.
Jack Chan's Weekly Update on Gold and Silver (02/11/2017)
Jack Chan charts both long- and short-term buy signals for gold and silver.
MGX Shareholders Ride a Rollercoaster (02/10/2017)
Bob Moriarty of 321 Gold chronicles MGX Minerals' wild ride from $0.69 to $2.75 to $0.92 in three weeks.
Volatility in the oil and gas markets continues, with prices plunging yet again in the recent chaos surrounding Greece's default negotiations and other global political uncertainties. But a rebound is inevitable, and Mackie Research's Bill Newman has his eye on companies that have managed to grow, step by step, even in hard times. In this interview with The Energy Report, Newman identifies companies with individual stories that will, in the end, defy the trend.
RJK and Winston Hit Big Gold (02/09/2017)
Bob Moriarty of 321 Gold profiles two gold explorers, RJK Explorations and Winston Gold, that he sees as low-risk, high-potential stocks.
Regeneus, an Australian regenerative medicine company, has entered into a collaboration with a major Japanese firm to manufacture its stem cell therapy Progenza, a move that may accelerate approval and that has a pair of analysts optimistic about the company's future.
After a relatively long period without significant news, Terraco Gold seems to have shifted a gear now, so The Critical Investor sat down with CEO Todd Hilditch for a company update.
Trevali Mining is transitioning to an owner-operator model at its Caribou zinc mine in New Brunswick, Canada, and analysts note that the company is positioned to take advantage of strong zinc fundamentals.
But What About that 'Big, Ugly, Red Candle'? (02/07/2017)
Precious metals expert Michael Ballanger discusses why technical analysis does not work in the precious metals arena.
Luminor Drives the Scout DS Forward (02/06/2017)
Veteran investor Bob Moriarty discusses Luminor Medical Technologies, whose Scout DS technology offers a noninvasive diabetic screen, measuring blood-sugar levels without taking blood.
Chinese and European economic activities are finally showing signs of strength, and in 2017, any severe corrections should be viewed as opportunities to position more strategically for long-term gains, says Lior Gantz, editor of Wealth Research Group.
Jack Chan: This Past Week in Gold (02/04/2017)
Technical analyst Jack Chan charts the latest moves in the gold and silver markets.
The Future of Cannabis Investing (02/03/2017)
The cannabis industry attained new highs in 2016, paving the way for some big changes this year, says Tom Beck, senior editor of Portfolio Wealth Global.
Pershing Gold has been going full speed ahead to advance the Relief Canyon mine in Nevada, leading some analysts to speculate that production could begin by the end of the year.
Victoria Gold's Eagle Is Getting Ready to Soar (02/02/2017)
Victoria Gold's Eagle project in the Yukon moved closer to production with the announcement of a debt facility to fund construction.
ContraVir's Hep B Drug Could Be a Game Changer (02/01/2017)
In light of a Q4/16 announcement by ContraVir Pharmaceuticals about the effectiveness of its compound targeting the hepatitis B virus (HBV), several analysts believe expanding its Phase 2a dose escalation trial could lead to positive results for a population that represents an unmet medical need, as well as for the company.
Companies Flocking to Japan for Biotech Deals (02/01/2017)
For the last two years, Japan has been at the forefront of accelerated approval for regenerative medicine products and has seen lots of licensing and contract manufacturing deals and M&A activity. Tokyo-based Colin Lee Novick, managing director of CJ PARTNERS, surveys the landscape, discussing recent tie-ups, the effects of the recently passed 21st Century Cures Act in the U.S., and what may lie ahead.
BonTerra Hits Big Gold Numbers (02/01/2017)
Bob Moriarty of 321 Gold provides an update on BonTerra Resources after the release of high-grade drill results.
|"We are initiating coverage on NRG with a rating of Outperform."|
|"The development of MAG's Juanicipio continues to advance on schedule."|
|"ELY announced deals that add two important assets to its portfolio."|
|"PVG is our favorite midcap, single-asset gold producer."|
|"VIV looks like a most attractive stock; it is an immediate Strong Buy."|